TAK700 | malecare.org

Phase III Trial Comparing Orteronel (TAK-700) Plus Prednisone Against Placebo Plus Prednisone Fails

Reporting both negative clinical trial results is as important as reporting positive results. However, pharmaceutical companies often bury negative results. Fortunately (actually unfortunately because there were negative results) a Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed [...]

By Malecare|2020-02-04T11:36:51-05:00April 3rd, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, TAK700, Uncategorized|0 Comments

The Well Reviewed Guide to Advanced Prostate Cancer (A Survivor Perspective) Has Been Updated and is Now Available for a free Download

Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]

By Malecare|2017-10-19T10:47:58-04:00September 30th, 2014|2nd line hormone therapy, abiraterone acetate, adjuvant therapy, ADT, Advanced Prostate Cancer, Alpha Emitting Radio Therapy, Alpharadin (radium-223), Androgan Receptor Inhibitor, Bio Chemical Recurrence, biomarkers, bisphosphonates, Bone Health, Bone Metastases, Bone Mineral Density, CAB, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Combination Therapy, Cross Resistance, Cryotherapy, CTCs, denosumab - Xgeva, Diet, Diet and Supplements, Drugs & Treatments, Early Access Program (EAP), Early/Expanded Access Programs, End-Of-Life, enzalutamide, estrogen patches, FDA, Financial, Firmagon (degarelix), General Information, genetics, HIFU, Hormone Therapy, Hot Flashes, How We Live, immunotherapy, Incontinence, inflammation, ipilimumab, ketoconazole, Medicare/Medicaid, mental health, Metastases, MRIs, NCI, neuroendocrine prostate cancer, neutropenia, Nilandron, oligometastic, On The Horizon, Our Caretakers, Pain, perineural invasion, peripheral neuropathy, Personal Experiences, prognostic tools, Prostate Ponderings, Prostvac, Provenge, PSA, PSADT, Quality of Life, radiation proctitis, radiopharmaceuticals, Radiotherapy, Research, Revlimid (lenalidomide), salvage therapy, statins, supplements, survival, survivorship, TAK700, teleconferences, Uncategorized, Understanding APC, vaccines, Vitamine D3, weight gain, Xgeva, XL184, Xofigo, Xtandi, Zometa, Zytiga|1 Comment

TAK-700 Fails to Offer A Survival Extension

Much of my reporting about ASCO 2014 has included only positive studies, but there is always a share of studies and trials that do not prove to be of a direct positive value to men with Advanced Prostate Cancer. Today’s report includes one of these negative reports. Remember, a negative report is as valuable as [...]

By Malecare|2021-02-17T11:03:12-05:00June 9th, 2014|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, TAK700, Uncategorized|1 Comment

Takeda Un-blinds & Halts the Phase 3 Study of Orteronel in Men with mCRPC That Progressed Post-Chemotherapy

A press release made yesterday brought some bad news to the advanced prostate cancer community. Takeda Pharmaceutical Company Limited (“Takeda”) announced that it has un-blinded and stopped the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed [...]

By Malecare|2017-10-19T10:49:37-04:00July 26th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, TAK700|0 Comments

Attacking Androgen Receptor Signaling In Castrate Resistant Prostate Cancer

Advanced prostate cancer eventually progresses and becomes castration resistant (CRPC) despite the fact that it is exquisitely sensitivity to androgen deprivation therapy. There has been recent evidence that prostate cancer progression at the CRPC stage is still mediated by androgen receptor signaling, so it seems that subsequent androgen receptor targeting may further contribute to disease [...]

By Malecare|2017-10-19T10:51:57-04:00October 20th, 2011|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, MDV3100, On The Horizon, TAK700, Uncategorized, Understanding APC|0 Comments